Pfizer Stock Down 33% Over Decade, Earnings Expected to Decline Through 2029
PFE is trading near its 52-week low of $23.11 (4.0% above the low).
Summary
A Barrons.com analysis highlights Pfizer's significant stock underperformance, down 33% over the past decade and ranking as the worst among large-cap peers in 2026. This bearish outlook, attributed to patent expirations, a weak pipeline, and the inability to follow up on its COVID-19 windfall, persists despite recent positive news regarding drug settlements and promising clinical trial data. The report projects Pfizer's earnings to decline almost 10% this year and continue dropping annually through 2029, signaling a challenging long-term trajectory. Furthermore, the company's high dividend yield of over 7% and lack of stock buybacks raise questions about capital allocation. Barrons.com specifically identifies Pfizer as not being among the healthcare stocks recommended for their dividends.
At the time of this announcement, PFE was trading at $24.04 on NYSE in the Life Sciences sector, with a market capitalization of approximately $137B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.